Vishak K Acharya1, Mahesha Padyana2, Unnikrishnan B3, Anand R4, Preethm R Acharya5, Divya Jyoti Juneja6. 1. Associate Professor, Department of Chest Medicine, Kasturba Medical College Mangalore (Manipal University), India . 2. Senior Resident, Department of General Medicine, Kasturba Medical College Mangalore (Manipal University), India . 3. Professor and Head, Department of Community Medicine, Kasturba Medical College Mangalore, Mangalore (Manipal University), India . 4. Professor and Head, Department of Chest Medicine, Kasturba Medical College Mangalore, Mangalore (Manipal University), India . 5. Associate Professor, Department of Chest Medicine, Kasturba Medical College Mangalore, Mangalore (Manipal University), India . 6. MBBS Student, Kasturba Medical College Mangalore, Mangalore (Manipal University), India .
Abstract
BACKGROUND: Community Acquired Pneumonia (CAP) is the most common respiratory tract infection in day to day practice. The knowledge of organism commonly causative of CAP helps in early empirical treatment initiation. AIM: To study the microbiological profile of patients with community acquired pneumonia and to study drug sensitivity pattern. METHODS: Hospital based cross sectional study among 100 patients with CAP was conducted in a tertiary care hospital of Southern India. Sputum culture showed that out of 100 patients 39 had an identifiable etiology with 12 patients having evidence of mixed infection. RESULT: Micro-organisms isolated in sputum culture were Streptococcus pneumoniae (31%) followed by, Pseudomonas pyogens (15%), Klebsiella pneumoniae (13%). AFB smear was found to be positive in 6 patients. Organisms were found to be sensitive for piperacillin plus tazobactum (41%), aminoglycocides (amikacin-46%, gentamicin-31%), third generation cephalosporins (Cefotaxim-36%, Ceftriaxone-18%) and macrolides (Erythromicin-31%, Azithromycin-18%). Sensitivity to chloramphenicol was observed in 31% sputum culture positive patients. Ciprofloxacin sensitivity was seen among 49%. CONCLUSION: Most of the organisms were found to be sensitive to monotherapy with extended spectrum beta lactamases, third generation cephalosporins, fluroquinolones, macrolides.
BACKGROUND: Community Acquired Pneumonia (CAP) is the most common respiratory tract infection in day to day practice. The knowledge of organism commonly causative of CAP helps in early empirical treatment initiation. AIM: To study the microbiological profile of patients with community acquired pneumonia and to study drug sensitivity pattern. METHODS: Hospital based cross sectional study among 100 patients with CAP was conducted in a tertiary care hospital of Southern India. Sputum culture showed that out of 100 patients 39 had an identifiable etiology with 12 patients having evidence of mixed infection. RESULT: Micro-organisms isolated in sputum culture were Streptococcus pneumoniae (31%) followed by, Pseudomonas pyogens (15%), Klebsiella pneumoniae (13%). AFB smear was found to be positive in 6 patients. Organisms were found to be sensitive for piperacillin plus tazobactum (41%), aminoglycocides (amikacin-46%, gentamicin-31%), third generation cephalosporins (Cefotaxim-36%, Ceftriaxone-18%) and macrolides (Erythromicin-31%, Azithromycin-18%). Sensitivity to chloramphenicol was observed in 31% sputum culture positive patients. Ciprofloxacin sensitivity was seen among 49%. CONCLUSION: Most of the organisms were found to be sensitive to monotherapy with extended spectrum beta lactamases, third generation cephalosporins, fluroquinolones, macrolides.
Entities:
Keywords:
Coastal southern india; Community acquired pneumonia; Drug sensitivity; Microbiological profile
Authors: Lionel A Mandell; Richard G Wunderink; Antonio Anzueto; John G Bartlett; G Douglas Campbell; Nathan C Dean; Scott F Dowell; Thomas M File; Daniel M Musher; Michael S Niederman; Antonio Torres; Cynthia G Whitney Journal: Clin Infect Dis Date: 2007-03-01 Impact factor: 9.079
Authors: Raúl Riquelme O; Mauricio Riquelme O; María Luisa Rioseco Z; Valeria Gómez M; Rodrigo Gil D; Antonio Torres M Journal: Rev Med Chil Date: 2006-06-19 Impact factor: 0.553